| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Yaping Sun | |
| Isao Tawara | |||
| Pavan Reddy | |||
| Tomomi Toubai | |||
| P2860 | cites work | The receptor for the cytotoxic ligand TRAIL | Q24310481 |
| Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95 | Q24314819 | ||
| KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy | Q79973289 | ||
| Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy | Q80141484 | ||
| Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation | Q80388681 | ||
| Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease | Q80825838 | ||
| Target antigens determine graft-versus-host disease phenotype | Q80884497 | ||
| Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ | Q80952289 | ||
| Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD | Q81014631 | ||
| Protective conditioning for acute graft-versus-host disease | Q81279975 | ||
| Regulatory T cells | Q81342301 | ||
| Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells | Q81357564 | ||
| A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses | Q81357571 | ||
| Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells | Q81377803 | ||
| TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse | Q81546508 | ||
| Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination | Q82312167 | ||
| Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR | Q83885898 | ||
| CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease | Q34525987 | ||
| The B7-CD28 superfamily | Q34575331 | ||
| Perforin-mediated target-cell death and immune homeostasis | Q34584322 | ||
| Cytolytic pathways in haematopoietic stem-cell transplantation | Q34632083 | ||
| Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. | Q34834459 | ||
| The complementary roles of deletion and regulation in transplantation tolerance | Q35058547 | ||
| Contrasting alloreactive CD4+ and CD8+ T cells: there's more to it than MHC restriction | Q35072094 | ||
| T cell anergy and costimulation | Q35096703 | ||
| Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets | Q35158939 | ||
| Umbilical-cord blood transplantation for the treatment of cancer | Q35166819 | ||
| Immunobiology of acute graft-versus-host disease | Q35558501 | ||
| Antigen presentation in graft-vs-host disease | Q35602916 | ||
| Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat | Q35605951 | ||
| Cytokine dysregulation and acute graft-versus-host disease | Q35607602 | ||
| Pathophysiology of acute graft-versus-host disease | Q35634710 | ||
| Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. | Q35804422 | ||
| How I treat refractory acute GVHD. | Q35828633 | ||
| Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. | Q35828810 | ||
| Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. | Q35847425 | ||
| New approaches for preventing and treating chronic graft-versus-host disease | Q35847596 | ||
| In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets | Q35847952 | ||
| Critical role of host gammadelta T cells in experimental acute graft-versus-host disease | Q35847964 | ||
| Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease | Q35848361 | ||
| Peyer patches are not required for acute graft-versus-host disease after myeloablative conditioning and murine allogeneic bone marrow transplantation | Q35848487 | ||
| Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine | Q35848654 | ||
| Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response | Q35849658 | ||
| New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance | Q35876745 | ||
| Interleukin-18: recent advances | Q35953062 | ||
| Genetic polymorphisms predicting the outcome of bone marrow transplants | Q35964779 | ||
| Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function | Q35996711 | ||
| IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation | Q36001183 | ||
| Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs | Q36072414 | ||
| Non-HLA immunogenetics in hematopoietic stem cell transplantation | Q36221377 | ||
| Cytolytic pathways used by effector cells derived from recipient naive and memory T cells and natural killer cells in resistance to allogeneic hematopoietic cell transplantation | Q36336443 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity | Q28139188 | ||
| CD95's deadly mission in the immune system | Q28142072 | ||
| The danger model: a renewed sense of self | Q28214633 | ||
| The B7 family revisited | Q28240070 | ||
| TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis | Q28257134 | ||
| Host-reactive CD8+ memory stem cells in graft-versus-host disease | Q28281894 | ||
| Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis | Q28591879 | ||
| Toll-like receptor control of the adaptive immune responses | Q29547305 | ||
| Signalling pathways of the TNF superfamily: a double-edged sword | Q29616428 | ||
| Nitric oxide and the immune response | Q29617591 | ||
| Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants | Q29619458 | ||
| Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer | Q29619483 | ||
| Role of endogenous peptide in human alloreactive cytotoxic T cell responses | Q30311400 | ||
| Leukocyte migration and graft-versus-host disease | Q30479618 | ||
| A uniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications | Q33267303 | ||
| Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells | Q33707814 | ||
| Homeostatic proliferation is a barrier to transplantation tolerance | Q33731951 | ||
| Pathophysiologic mechanisms of acute graft-vs.-host disease | Q33793177 | ||
| Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia | Q33857573 | ||
| The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation | Q33898254 | ||
| Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma | Q33929802 | ||
| The role of chemokine receptors in primary, effector, and memory immune responses | Q33932742 | ||
| New strategies for bone marrow transplantation | Q34046829 | ||
| Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity | Q34057782 | ||
| NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. | Q34078681 | ||
| T cells require TRAIL for optimal graft-versus-tumor activity | Q34158517 | ||
| Dendritic cells in transplantation--friend or foe? | Q34241103 | ||
| Mixed chimerism and transplant tolerance | Q34241143 | ||
| Haematopoietic cell transplantation as immunotherapy | Q34253590 | ||
| The role of peripheral T-cell deletion in transplantation tolerance | Q34262660 | ||
| Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model | Q34265880 | ||
| Molecules and mechanisms of the graft-versus-leukaemia effect | Q34318010 | ||
| Role of adhesion molecules in activation signaling in T lymphocytes | Q34337765 | ||
| The molecular and functional characterization of a dominant minor H antigen, H60. | Q34473903 | ||
| Interferon-gamma-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice | Q36851990 | ||
| Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation | Q37371294 | ||
| Fas ligand- mediated killing by intestinal intraepithelial lymphocytes. Participation in intestinal graft-versus-host disease | Q37377818 | ||
| The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis | Q37385249 | ||
| Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. | Q37387081 | ||
| Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease | Q37388077 | ||
| Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. | Q37388260 | ||
| T-lymphocyte-antigen interactions in transplant rejection | Q38139921 | ||
| Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts | Q39244446 | ||
| Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. | Q39737971 | ||
| Memory CD4+ T cells do not induce graft-versus-host disease | Q39778135 | ||
| The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies | Q40165690 | ||
| Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necro | Q40393771 | ||
| Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease | Q40627364 | ||
| Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation | Q40689796 | ||
| Human minor histocompatibility antigens | Q40700412 | ||
| The immunological synapse and CD28-CD80 interactions. | Q40767962 | ||
| T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. | Q40846424 | ||
| Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. | Q40851124 | ||
| Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. | Q40858697 | ||
| Class I-restricted alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides. | Q41046602 | ||
| Role of indirect allorecognition in allograft rejection | Q41091908 | ||
| Induction of apoptosis in mature T cells by tumour necrosis factor | Q41293478 | ||
| Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease | Q41640832 | ||
| Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines | Q41699354 | ||
| Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production | Q41908710 | ||
| Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers | Q42143820 | ||
| Negative selection of T cells causing lethal graft-versus-host disease across minor histocompatibility barriers. Role of the H-2 complex | Q42259756 | ||
| Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation | Q42539543 | ||
| Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. | Q43605522 | ||
| Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects | Q43852100 | ||
| Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene | Q44248916 | ||
| Murine graft-versus-host disease in an F1-hybrid model using IFN-gamma gene knockout donors. | Q44329356 | ||
| CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation | Q44408941 | ||
| Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia | Q44499780 | ||
| FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigennonidentical unrelated canine model1 | Q44632260 | ||
| IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease | Q44892232 | ||
| Association of Foxp3 regulatory gene expression with graft-versus-host disease | Q44917891 | ||
| Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. | Q45009365 | ||
| Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease | Q45018029 | ||
| Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease | Q45053959 | ||
| Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation | Q45866646 | ||
| HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia | Q45882160 | ||
| Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes | Q45888667 | ||
| Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. | Q46672540 | ||
| Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism | Q46763980 | ||
| Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning | Q47231959 | ||
| Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome | Q47359749 | ||
| Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease | Q47371499 | ||
| IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation | Q47602546 | ||
| Phenotype, function and chimaerism of monocyte‐derived blood dendritic cells after allogeneic haematopoietic stem cell transplantation | Q47604670 | ||
| Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation | Q71929801 | ||
| Interleukin-12 inhibits murine graft-versus-host disease | Q72030978 | ||
| Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation | Q72311523 | ||
| Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice | Q72372127 | ||
| Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts | Q72446561 | ||
| Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice | Q72620596 | ||
| Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens | Q72700860 | ||
| Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice | Q72776658 | ||
| Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients | Q73113896 | ||
| Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors | Q73126126 | ||
| Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse | Q73153290 | ||
| Enhancement of MHC class I-stimulated alloresponses by TNF/TNF receptor (TNFR)1 interactions and of MHC class II-stimulated alloresponses by TNF/TNFR2 interactions | Q73166203 | ||
| Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants | Q73205710 | ||
| Fas-deficient lpr mice are more susceptible to graft-versus-host disease | Q73289694 | ||
| The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity | Q73330338 | ||
| Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients | Q73509907 | ||
| Fas-mediated cholangiopathy in the murine model of graft versus host disease | Q73584922 | ||
| Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells | Q73642913 | ||
| Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice | Q73886957 | ||
| Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines | Q73894705 | ||
| Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease | Q74122363 | ||
| Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections | Q74138254 | ||
| Acute graft-versus-host disease does not require alloantigen expression on host epithelium | Q74221421 | ||
| Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation | Q74444949 | ||
| Role of the passive apoptotic pathway in graft-versus-host disease | Q74500191 | ||
| Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease | Q74541853 | ||
| Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies | Q74576875 | ||
| NK cells: a lesson from mismatched hematopoietic transplantation | Q74675080 | ||
| Interleukin 7 worsens graft-versus-host disease | Q74805797 | ||
| High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation | Q75197654 | ||
| Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection | Q77218507 | ||
| Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients | Q77228239 | ||
| Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model | Q77493969 | ||
| Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients | Q77601922 | ||
| In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens | Q77859052 | ||
| Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process | Q77975018 | ||
| Prevention of graft versus host disease by inactivation of host antigen-presenting cells | Q78016071 | ||
| Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor | Q78409932 | ||
| Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease | Q78409988 | ||
| Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation | Q78410438 | ||
| Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide | Q78518647 | ||
| CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT | Q78523396 | ||
| Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients | Q78773723 | ||
| Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction | Q78782071 | ||
| Role of CXCR3-induced donor T-cell migration in acute GVHD | Q79149798 | ||
| T-cell subsets: the more the merrier | Q79616741 | ||
| Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease | Q79674881 | ||
| In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment | Q36350708 | ||
| Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? | Q36354616 | ||
| Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease | Q36357597 | ||
| A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease | Q36363382 | ||
| Adoptive transfer of allogeneic antigen-specific T cells. | Q36363385 | ||
| Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease | Q36366324 | ||
| The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice | Q36366817 | ||
| Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease | Q36368026 | ||
| Pathophysiology of graft-versus-host disease | Q36368101 | ||
| Genetics of risk factors for graft-versus-host disease | Q36368106 | ||
| A human minor histocompatibility antigen resulting from differential expression due to a gene deletion | Q36370375 | ||
| Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation | Q36370863 | ||
| Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis | Q36377260 | ||
| Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance | Q36401145 | ||
| FOXP3: of mice and men. | Q36427333 | ||
| Minor histocompatibility antigens: from transplantation problems to therapy of cancer | Q36489688 | ||
| Induction of tumor immunity following allogeneic stem cell transplantation | Q36490755 | ||
| Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease | Q36505142 | ||
| Immunogenomics of unrelated hematopoietic cell transplantation | Q36548014 | ||
| The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. | Q36552462 | ||
| Nod-like proteins in immunity, inflammation and disease | Q36655897 | ||
| Immunobiology of allogeneic hematopoietic stem cell transplantation | Q36665305 | ||
| T cell-directed therapies: lessons learned and future prospects | Q36688370 | ||
| New directions in the genomics of allogeneic hematopoietic stem cell transplantation | Q36714821 | ||
| Thymic development and peripheral homeostasis of regulatory T cells. | Q36738380 | ||
| CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans | Q47704184 | ||
| Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism | Q47745301 | ||
| The biology of graft-versus-host reactions | Q47809350 | ||
| Inhibition of graft-versus-host disease by double-negative regulatory T cells | Q47817030 | ||
| Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. | Q49165929 | ||
| L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. | Q50796687 | ||
| Detection of nitric oxide by electron paramagnetic resonance spectroscopy during rejection and graft-versus-host disease after small-bowel transplantation in the rat | Q51685233 | ||
| Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. | Q51994114 | ||
| Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. | Q52002812 | ||
| TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x bm12)F1 mice. | Q52014017 | ||
| A major role for the Fas pathway in acute graft-versus-host disease. | Q52045436 | ||
| In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. | Q53589050 | ||
| Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. | Q54073234 | ||
| Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy | Q56777948 | ||
| Differential TCR Signaling Regulates Apoptosis and Immunopathology during Antigen Responses In Vivo | Q56880742 | ||
| Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment | Q56906119 | ||
| Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts | Q56909451 | ||
| In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice | Q56909694 | ||
| Identification of a graft versus host disease-associated human minor histocompatibility antigen | Q56929110 | ||
| Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD | Q57252628 | ||
| IFN differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract | Q57252630 | ||
| Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation | Q57252633 | ||
| TGF- in allogeneic stem cell transplantation: friend or foe? | Q57252637 | ||
| Relation of an Interleukin-10 Promoter Polymorphism to Graft-versus-Host Disease and Survival after Hematopoietic-Cell Transplantation | Q58814550 | ||
| Foxp3-dependent programme of regulatory T-cell differentiation | Q59084714 | ||
| Influence of SHIP on the NK Repertoire and Allogeneic Bone Marrow Transplantation | Q59280520 | ||
| Nitric oxide formation as predictive parameter for acute graft-versus-host disease after human allogeneic bone marrow transplantation | Q61906319 | ||
| Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens | Q67898770 | ||
| Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease | Q67903035 | ||
| Different types of allospecific CTL clones identified by their ability to recognize peptide loading-defective target cells | Q68036519 | ||
| Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease | Q68140704 | ||
| Risk factors for acute graft-versus-host disease | Q68218218 | ||
| Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens | Q68578028 | ||
| Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation | Q68928908 | ||
| Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma | Q69482387 | ||
| Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences | Q69873475 | ||
| T cell subsets and graft-versus-host disease | Q70037088 | ||
| Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation | Q70149552 | ||
| Rapid analysis of tumor necrosis factor-alpha mRNA expression during venoocclusive disease of the liver after allogeneic bone marrow transplantation | Q70563647 | ||
| Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation | Q70582290 | ||
| High frequencies of cytotoxic T cell precursors against minor histocompatibility antigens after HLA-identical BMT: absence of correlation with GVHD | Q70742852 | ||
| Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation | Q70812614 | ||
| Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease | Q70837443 | ||
| The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection | Q71017487 | ||
| Suppression of B-cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-alpha in mice with acute graft-versus-host disease | Q71100113 | ||
| Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease | Q71249479 | ||
| Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease | Q71870327 | ||
| P433 | issue | 4 | |
| P921 | main subject | pathophysiology | Q1135939 |
| P304 | page(s) | 197-214 | |
| P577 | publication date | 2007-07-03 | |
| P1433 | published in | Translational Research | Q15761127 |
| P1476 | title | Pathophysiology of acute graft-versus-host disease: recent advances | |
| P478 | volume | 150 |
| Q39445124 | Acute graft-vs.-host disease correlates with the disparity for the PECAM-1 S536N polymorphism only in the HLA-B44-like positive Tunisian recipients of HSCs |
| Q39006094 | Association between C-reactive protein levels in the first 1-3 days post-transplant and allogeneic immune reactions |
| Q37201903 | Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect. |
| Q44074652 | Challenges and prospects of adoptive immunotherapy in prevention and treatment of opportunistic mycoses in hematologic transplant recipients |
| Q37397003 | Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage. |
| Q37435506 | Dichotomous role of interferon-gamma in allogeneic bone marrow transplant |
| Q34393959 | Does minor histocompatibility antigen HA-1 disparity affect the occurrence of graft-versus-host disease in tunisian recipients of hematopoietic stem cells? |
| Q35865094 | Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease |
| Q38488050 | Early onset of acute GVHD indicates worse outcome in terms of severity of chronic GVHD compared with late onset |
| Q85209784 | Efficacy of pretreatment of allografts with methoxypolyethylene glycol-succinimidyl-propionic acid ester in combination with an anti-OX40L monoclonal antibody in relieving graft-versus-host disease in mice |
| Q39445089 | Evidence that erythrocyte DARC-positive phenotype can affect the GVHD occurrence after HLA-identical sibling HSCT. |
| Q37543256 | Fine-needle aspiration (FNA) and pleural fluid cytology diagnosis of benign metastasizing pleomorphic adenoma of the parotid gland in the lung: a case report and review of literature |
| Q46344148 | GVHD after chemotherapy conditioning in allogeneic transplanted mice. |
| Q33747297 | Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors |
| Q37942818 | Graft-vs-host disease following allogeneic hematopoietic cell transplantation |
| Q84360672 | Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex |
| Q37810081 | Immunoregulation of GVHD by triggering the innate immune system with CpG |
| Q36380188 | Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects |
| Q37086953 | In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations |
| Q36788495 | In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor |
| Q34683729 | Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation |
| Q33619021 | Kinetics of IFN-γ and IL-17 Production by CD4 and CD8 T Cells during Acute Graft-versus-Host Disease |
| Q87458801 | Mesenchymal stem cells suppress CD8+ T cell-mediated activation by suppressing natural killer group 2, member D protein receptor expression and secretion of prostaglandin E2, indoleamine 2, 3-dioxygenase and transforming growth factor-β |
| Q54936066 | Minimizing ICU Neurological Dysfunction with Dexmedetomidine-induced Sleep (MINDDS): protocol for a randomised, double-blind, parallel-arm, placebo-controlled trial. |
| Q39445130 | Mismatch for the minor histocompatibility antigen HA-2 and GVHD occurrence in HLA-A*0201-positive Tunisian recipients of HSCs. |
| Q37414672 | Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease |
| Q36932886 | Oral graft-versus-host disease. |
| Q34077479 | Pathogenesis and management of graft-versus-host disease. |
| Q37761297 | Progress and prospects: graft-versus-host disease |
| Q33396969 | Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. |
| Q45954189 | Sclerodermatous chronic graft-versus-host disease induced by host T-cell-mediated autoimmunity. |
| Q33685495 | Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation |
| Q37776504 | Solid Organ Transplant-Associated Acute Graft-Versus-Host Disease |
| Q28554554 | Spatiotemporal Dynamics of Dexmedetomidine-Induced Electroencephalogram Oscillations |
| Q37729354 | TLR4 inactivation protects from graft-versus-host disease after allogeneic hematopoietic stem cell transplantation |
| Q52971841 | The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease. |
| Q57538743 | The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the Treatment of Immune-Related Diseases: A Systematic Review |
| Q91664568 | The gut microbiota and graft-versus-host disease |
| Q41831790 | Transplantation with bone marrow stromal cells promotes wound healing under chemotherapy through altering phenotypes |
Search more.